27 results
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
20 May 09
Departure of Directors or Certain Officers
12:00am
and backlog related to acquisitions, in process R&D expense related to acquisitions, costs of restructuring, the impact of stock compensation expense … fees, transition costs and restructuring costs, fair value adjustments of inventory and backlog related to acquisitions, in process R&D expense
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
5 Jan 24
Results of Operations and Financial Condition
5:01pm
Technologies Serving Well - funded, High - growth Secular Markets Demographic Tailwinds 7 R&D $222B (2021)* NIH Grants $30.2B (2021)* R&D $60B (2021)* Estimated … R&D expenditure within HBIO markets US Federal $179B 2021 9.3% 2016 - 2021 Pre - clinical market $5B (2021) 5 7
Subset of blue - chip recurring
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
4 May 22
Harvard Bioscience Announces First Quarter 2022 Financial Results
7:01am
costs associated with ongoing global supply disruptions. We also funded growth investments in R&D and marketing. On a GAAP basis, we recorded … in the year. However, we will continue incremental investments in R&D to sustain double-digit growth over the long run.”
Quarterly Financial Results
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
25 Mar 03
Genomic Solutions Inc., a Harvard Bioscience company, completes acquisition of GeneMachines
12:00am
will be integrated with the Genomic Solutions commercial organization, while manufacturing, R&D and certain marketing and customer support personnel
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
1 Oct 14
Expected to Add $7.5 Million to $8.5 Million in Revenue in 2015
12:00am
of researchers worldwide."
Dr. James Morizio, President and former majority owner of TBSI, will become Director of R&D, Wireless Platform, of Harvard
8-K
EX-99.1
lhk f6pwhrk5c1
25 Nov 03
Harvard Bioscience Acquires Selected Assets of Hoefer 1-D Electrophoresis Business from Amersham Biosciences
12:00am
8-K
EX-99.1
o7yddv9 iq1q12s
15 Jun 01
Current report
12:00am
8-K
EX-99.1
3eb gq83idql9h
4 Aug 22
Harvard Bioscience Announces Second Quarter 2022 Financial Results
7:01am
8-K
EX-99.1
41c9rtmun2k783d
8 Mar 22
Harvard Bioscience Announces Fourth Quarter 2021 Financial Results
7:00am
8-K
EX-99.1
1m7xqw5at
1 Jun 05
Results of Operations and Financial Condition
12:00am
8-K
EX-99.1
65qj6t
30 Jul 04
Financial statements and exhibits
12:00am
8-K
EX-99
fk2olzv
4 Jan 06
Entry into a Material Definitive Agreement
12:00am